Fibrosis is when connective tissue from an injury or other circumstances thickens and scars, or when there is excess fibrous connective tissue in an organ after it has been exposed to a chronic disease. Unfortunately, the effects of fibrosis cannot be reversed, and there is currently no treatment that stops the disease from getting worse, although some treatments can deal with the symptoms temporarily.
Galectin Therapeutics, Inc. (NASDAQ: GALT) is currently undertaking its phase 2a pilot trial (NASHFX) with GR-MD-02 in non-alcoholic steatohepatitis (NASH) patients with advanced fibrosis. Although the study did not meet original expectations, Galectin’s larger scale, one year trial in patients with NASH cirrhosis has already enrolled 162 subjects, and top line results will be reported by the end of December 2017. The company considers it encouraging to see that GR-MD-02 has an important clinical effect in both moderate and severe cases of psoriasis. This further suggests that the substance can play a role for human diseases that could be related to NASH.
Galectin Therapeutics, Inc. is a biotechnology company focused on the science of galectins, a family of proteins, and drug development. With this expertise, the company creates new therapies for patients suffering from fibrotic diseases and cancer. Galectin works with a variety of partners in order to achieve cost effective and efficient development results within short time frames.
GALT is currently looking to enhance and market its lead compounds in liver fibrosis and cancer immunotherapies. The company has three key areas of focus: studying galectins, developing proprietary compounds for diseases, and advancing its discovery programs. All three work together in order to achieve the overall goal of creating new therapies for fibrotic diseases and cancer.
For more information, visit www.GalectinTherapeutics.com
